Skip to main content
OpenTrials
Completed

NCT Number: NCT05344690

SLMAP and EPO Genetic Polymorphism in Diabetic Retinopathy

A case-control study to assess the association between the risk of diabetic retinopathy in Egyptians and genetic polymorphism of both EPO and SLMAP genes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetic Retinopathy Cardiovascular Diseases Diabetes Complications Diabetes Mellitus Diabetic Angiopathies Endocrine System Diseases Eye Diseases Retinal Diseases Vascular Diseases

Age range

30 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ain Shams University Hospitals

Cairo, Abbasseya, Egypt

About this study

Traditional environmental risk factors, such as glycemic control and duration of diabetes, failed to fully explain why some individuals remain protected while others progress to severe diabetic retinopathy.

Several studies suggest variations in diabetic retinopathy prevalence depending on racial background and genetic polymorphism.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >30-60
  • Type 2 DM
  • Duration of diabetes from 5-10 years
  • Egyptian patients

Exclusion criteria

  • Other ophthalmic diseases not related to diabetes

Treatment and study plan

SLMAP and EPO genetic polymorphism

Genetic

Presence of EPO gene SNP rs551238 and SLMAP rs17058639 gene polymorphisms

Primary outcomes

  1. Association of SLMAP gene polymorphism and the risk of confirmed diabetic retinopathy diagnosis

    Time frame: At baseline (upon confirmed diagnosis of diabetic retinopathy)

    the odds ratio of being diagnosed with diabetic retinopathy in those with SLMAP rs17058639 single nucleotide polymorphism compared to wild type

  2. Association of EPO gene polymorphism and the risk of confirmed diabetic retinopathy diagnosis

    Time frame: At baseline (upon confirmed diagnosis of diabetic retinopathy)

    The odds ratio of being diagnosed with diabetic retinopathy in those with EPO rs551238 single nucleotide polymorphism compared to wild type

Secondary outcomes

  1. The association of confounding factors on the incidence of diabetic retinopathy

    Time frame: At baseline

    A multiple logistic regression model will be fitted to assess the association of diabetic retinopathy to confounders (microalbuminuria, lipid profile, age, gender,...etc.)

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

Evaluation of the Relationship Between SLMAP and EPO Genetic Polymorphism and the Risk of Diabetic Retinopathy in Egyptian Diabetic Patients: A Case-Control Study

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Apr 25, 2022
Registry last updated
Feb 7, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.